Biobank

Olink® Insight Unveils Open-access Map of the Human Proteome, Aiding Biomarker Discovery and Understanding of Disease

Retrieved on: 
Tuesday, April 2, 2024
UKB, Health, Kingdom of Poland, Prostate cancer, Chronic lymphocytic leukemia, CLL, Disease, Partnership, Risk, Biomarker, Research, FCRL2, Protein, Biology, Medicine, Biobank, Data, UK Biobank, Pharmaceutical industry

In April 2023, the UK Biobank Pharma Proteomics Project (UKB-PPP) released data produced from over 50,000 samples analyzed using the Olink® Explore platform.

Key Points: 
  • In April 2023, the UK Biobank Pharma Proteomics Project (UKB-PPP) released data produced from over 50,000 samples analyzed using the Olink® Explore platform.
  • The UKB-PPP is the largest population-scale proteomics study to date, yielding an unprecedented view into the biology of diseased and healthy individuals over a 10-year period.
  • By combining protein measurements with longitudinal healthcare data for each of the individuals, Olink derived the estimated effects of ~3,000 proteins on the future risk of disease.
  • Olink Insight is a free, web-based platform that puts the results of advanced computational data analysis into the hands of non-data scientists.

GTG Global Collaborations and Innovation Update

Retrieved on: 
Tuesday, March 26, 2024
Breast cancer, Health, General practice, Professor, BRCA, Public, Public health, Disease, GTG, Risk, Patient, PRS, Research, ASX, Breast, Mammography, University, Royal Melbourne Hospital, Trial of the century, WHI, Risk assessment, Sonneborn–Berger score, Council, Biobank, Publication, Clinical trial, Cancer, CLIA, Medical research, Colorectal cancer, University of Melbourne, Government, UK Biobank, Pharmaceutical industry

MELBOURNE, Australia, March 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to highlight a summary of the Company’s commitment to innovation.

Key Points: 
  • MELBOURNE, Australia, March 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to highlight a summary of the Company’s commitment to innovation.
  • GTG is one of the co-co-principal investigators of this trial led by Professor Jon Emery.
  • GTG regards adding new expanded risk assessment tests to the company’s portfolio as a critical step in improving patient care.
  • Leveraging this approach GTG is expanding the portfolio with the following new tests:
    Leveraging the BRCA-modifier research projects GTG will develop a test that incorporates high penetrant pathogenic variant risk with PRS.

New Data Show ClearNote Health’s Epigenomic Platform Provides a Novel Tissue-Free, Liquid Biopsy-Based Approach to Identify Potential Predictive Biomarker Candidates to Radioligand Therapy Response in Patients With Pancreatic Neuroendocrine Tumors

Retrieved on: 
Tuesday, March 26, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Plasma, Novartis, Nucleic acid thermodynamics, Patient, Biomarker, DNA, Cancer, Virtuoso, Oslo University Hospital, Rikshospitalet, Lutetium (177Lu) oxodotreotide, Medicine, Biobank, Somatostatin, FDA, Medical imaging

Differences in plasma-derived cell free DNA (cfDNA) 5hmC profiles after administration of Lutathera revealed biological responses consistent with radioligand therapy mechanism of action hypothesis.

Key Points: 
  • Differences in plasma-derived cell free DNA (cfDNA) 5hmC profiles after administration of Lutathera revealed biological responses consistent with radioligand therapy mechanism of action hypothesis.
  • “Our research collaboration with Novartis has demonstrated the power of ClearNote Health’s cutting-edge epigenomic technology in the interrogation of predictive biomarkers of radioligand therapy response from a single blood draw,” said Dave Mullarkey, CEO of ClearNote Health.
  • The comparison of plasma-derived cfDNA 5hmC profiles revealed differences that distinguish patients responding to therapy from those not responding before and on treatment.
  • This collaboration underscores ClearNote Health's commitment to empowering biopharmaceutical innovation in developing better drugs through cutting-edge molecular diagnostic technologies.

Estonia National Biobank Selects PacBio to Sequence 10,000 Whole Genomes

Retrieved on: 
Wednesday, March 27, 2024
Cardiology, Civil service commission, Health, Cardiovascular disease, Pseudogene, Cell, Genetics, Mental, Abraxis BioScience, Patient, Female, Cancer, University, Biology, Biobank, Epigenome, Genomics, European Commission, Economics, Medicine, Pharmaceutical industry

MENLO PARK, Calif., March 27, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that the University of Tartu, host of Estonia's National Biobank, has chosen the Revio HiFi sequencing system to sequence 10,000 whole human genomes and unlock new insights from its populational health data. The announcement follows funding from the European Commission and the Estonian government to help Estonia adopt personalized medicine at scale and adapt public health systems to the biology of its population. The University will also support the European Union's 1+ Million Genomes initiative, which seeks to boost innovation in healthcare across Europe.

Key Points: 
  • The University will also support the European Union's 1+ Million Genomes initiative , which seeks to boost innovation in healthcare across Europe.
  • 10,000 whole human genomes will be sequenced and analyzed by the Institute of Genomics at the University of Tartu using Revio.
  • "The team chose PacBio HiFi technology over other long- and short-read offerings because of its ability to sequence complete and accurate genomes at competitive economics and scale.
  • In addition to this 10,000-genome project, the Biobank team is looking to secure funding to sequence the entire biobank of over 200,000 samples to drive advances in health care globally.

Laboratory Information Management System (LIMS) Market Size to Grow by USD 907.08 million from 2023 to 2027, Market growth at 9.08% CAGR expected during the forecast period, Technavio

Retrieved on: 
Tuesday, March 26, 2024
Cloud, PerkinElmer, Laboratory information management system, Informatics, Component, Health, Paperless office, Laboratory, Saas, Automation, Thermo Fisher Scientific, Risk, ROW, ISO 17025, Privacy, Data management, Documentation, Biobank, LIMS, Research, AI, Food, Machine learning, ISO/IEC 17025, Growth, Abbott Laboratories, ERP, Software, Illumina, Inc., Comp, Life, ISO, Hardware

By geography, the global laboratory information management system (lims) market is segmented into North America, Europe, Asia, and Rest of World (ROW).

Key Points: 
  • By geography, the global laboratory information management system (lims) market is segmented into North America, Europe, Asia, and Rest of World (ROW).
  • The report provides actionable insights and estimates the contribution of all regions to the growth of the global laboratory information management system (lims) market.
  • Driving Forces in the LIMS Market:
    Stringent compliance and governmental regulations propel the growth of the Laboratory Management System (LIMS) market.
  • Growth of the Laboratory Information Management System (LIMS) Market industry across North America, Europe, Asia, and Rest of World (ROW)
    Gain instant access to 17,000+ market research reports.

Team SAMBAI, Yemaachi Biotech, Named as Recipient of Prestigious Cancer Grand Challenges Award

Retrieved on: 
Wednesday, March 6, 2024
Science, Biotechnology, Research, Oncology, Health, Data Management, Technology, Genetics, Incidence, Doctor of Philosophy, Cancer Research UK, Prostate, National Cancer Institute, Breast, Biobank, Medicine, Patient, Factorization of polynomials, Genomics, Health equity, Diagnosis, Mortality, Cancer, Pharmaceutical industry

Yemaachi today announced that a global, interdisciplinary team of researchers, including Yemaachi CEO & Co-founder Yaw Bediako, has been named a recipient of a Cancer Grand Challenges award of up to $25 million over five years to advance research on cancer inequities.

Key Points: 
  • Yemaachi today announced that a global, interdisciplinary team of researchers, including Yemaachi CEO & Co-founder Yaw Bediako, has been named a recipient of a Cancer Grand Challenges award of up to $25 million over five years to advance research on cancer inequities.
  • “We are confident that this work will be fruitful and will contribute to innovations that will benefit patients globally.
  • We are honored by Team SAMBAI’s belief in our scientific work and impact-driven mission.”
    Inequities in cancer prevention, screening, diagnosis, treatment, and research lead to disparities in cancer incidence and mortality and are a major public health concern.
  • Cancer Grand Challenges is a global funding initiative, co-founded by Cancer Research UK and the National Cancer Institute in the US, that supports a community of diverse, global teams to come together, think differently and take on cancer’s toughest challenges.

Cell Cryopreservation Market Research Report 2024 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 12, 2024
Biotechnology, Health, Medical Devices, Conditional sentence, Cryopreservation, Regenerative medicine, Cell, Research, Infertility, B cell, IVF, Risk, Tissue engineering, COVID-19, Sigma-Aldrich, Biobank, Stem cell, Prevalence

The "Cell Cryopreservation Market Size, Share & Trends Analysis Report By Product (Cell Freezing Media, Equipment), By Application (Stem Cells, Sperm Cells), By End-use (Biobanks, IVF), By Region, And Segment Forecasts, 2024 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cell Cryopreservation Market Size, Share & Trends Analysis Report By Product (Cell Freezing Media, Equipment), By Application (Stem Cells, Sperm Cells), By End-use (Biobanks, IVF), By Region, And Segment Forecasts, 2024 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The increased demand for cost-effective cryopreservation medium has stemmed from increased research & development (R&D) activities to create advanced medicines.
  • For example, Merck KGaA's Sigma Aldrich brand provides frozen media solutions for stem cell applications while ensuring optimal recovery and cell survival, thus, propelling the cryopreservation market growth.
  • Additionally, developments in freezing media formulation and cryopreservation techniques, as well as leveraging cryopreservation freezing media applications in fields such as tissue engineering, cellular treatment, and stem cell research, have driven the market at a substantial rate.

GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia

Retrieved on: 
Sunday, December 10, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Acute myeloid leukemia, LDAC, Safety, National Cancer Institute, ASH, Leukemia, Cellular, IIT, Cytogenetics, HCT, Pedal, Patient, Inflammation, Male, Cytarabine, Biobank, University, Transplant, AML, MD Anderson Cancer Center, Cancer, Society, Myelodysplastic syndrome, Cladribine, Haematopoietic system, Venetoclax, Pharmaceutical industry, Glycomimetic

“These findings underscore the broad potential of uproleselan, if successfully developed in combination with existing therapies, to benefit people with heterogeneous forms of AML.

Key Points: 
  • “These findings underscore the broad potential of uproleselan, if successfully developed in combination with existing therapies, to benefit people with heterogeneous forms of AML.
  • Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II
    This Phase 1b/2 clinical trial evaluated safety, tolerability, and preliminary efficacy of uproleselan added to cladribine and LDAC in patients with ts-AML.
  • This rare, high-risk study population is defined by prior chemotherapy treatment of a previous hematologic disorder, such as myelodysplastic syndrome.
  • Study investigators concluded these data support this low-risk approach to marrow blast reduction and disease control in preparation for HCT.

ISBER Launches New Best Practices: Recommendations for Repositories, Fifth Edition

Retrieved on: 
Monday, December 4, 2023
International Society, Research, Best practice, Organization, ISBER, Biopreservation, Availability, Biology, Ecosystem, Science, Biorepository, Fifth Edition, Biophysical environment, Biobank, Knowledge, Education, Book

VANCOUVER, BC, Dec. 4, 2023 /PRNewswire-PRWeb/ -- The International Society for Biological and Environmental Repositories (ISBER) announces the release of the ISBER Best Practices: Recommendations for Repositories, Fifth Edition. This is the definitive best practices guide for biological and environmental repositories across the world. (Available for download at www.isber.org/bpr).

Key Points: 
  • ISBER Launches New Best Practices Recommendations for Repositories, Fifth Edition at https://www.isber.org/page/bpr
    VANCOUVER, BC, Dec. 4, 2023 /PRNewswire-PRWeb/ -- The International Society for Biological and Environmental Repositories (ISBER) announces the release of the ISBER Best Practices: Recommendations for Repositories, Fifth Edition.
  • ISBER Best Practices: Recommendations for Repositories is a guidance document that reflects the collective experience of ISBER members and other repository professionals.
  • ISBER Launches New Best Practices Recommendations for Repositories, Fifth Edition at https://www.isber.org/page/bpr .
  • "The Fifth Edition of ISBER Best Practices stands as a testament to the altruistic spirit that fuels progress in our community" – Emma Snapes, Editor-in-Chief of the ISBER Best Practices Fifth Edition.

Human Biome Announces Prediction of first-in class, Biosynthetic Microbiome Against Silent Pandemic of Antibiotic-Resistant Bacteria and Doses First Patients in Contextual FMT Study to validate it

Retrieved on: 
Tuesday, October 31, 2023
NGB, Drug discovery, Doctor of Philosophy, Death, HBI, CDC, ARB, Microbiota, Biobank, Public, FMT, Cancer, Patient, Platform, Antibiotics

WARSAW, Poland, Oct. 31, 2023 /PRNewswire/ -- This is a major milestone for Human Biome, the field of microbiome medicine and whole epidemiology.

Key Points: 
  • WARSAW, Poland, Oct. 31, 2023 /PRNewswire/ -- This is a major milestone for Human Biome, the field of microbiome medicine and whole epidemiology.
  • Antibiotic resistance is a growing threat to public health, and new treatments are urgently needed.
  • The New-Generation Biotherapeutic (NGB) drug candidate has the potential to provide a new paradigm in preventing antibiotic-resistant bacteria (ARB) infections.
  • Now, we have predicted fully synthetic microbiome drug composition and our AI-based analysis confirms its efficacy – commented CEO and R&D Director of Human Biome Jaroslaw Bilinski MD, PhD.